Diane S. Aschenbrenner is a former member of the faculty at Notre Dame of Maryland University and the Johns Hopkins University School of Nursing. She coordinates Drug Watch :
Am J Nurs. 2023 Feb 1;123(2):27. doi: 10.1097/01.NAJ.0000919728.07518.8e.
Terlipressin (Terlivaz) has been approved as the first drug to treat hepatorenal syndrome.The drug may cause serious or fatal respiratory failure. Nurses should confirm that patients have an oxygen saturation level by pulse oximetry of at least 90% in order to start therapy.
特利加压素（Terlivaz）已被批准为治疗肝肾综合征的第一种药物。该药物可能导致严重或致命的呼吸衰竭。护士应通过脉搏血氧饱和度仪确认患者的氧饱和度至少为 90%，然后开始治疗。
